Last reviewed · How we verify
Albiglutide 50mg
Albiglutide 50mg, marketed by GlaxoSmithKline, is a GLP-1 receptor agonist with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-acting formulation, which enhances patient convenience. The primary risk is the impending patent expiry, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Albiglutide 50mg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects (PHASE4)
- Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus (PHASE3)
- An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide . (PHASE1)
- A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. (PHASE3)
- A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albiglutide 50mg CI brief — competitive landscape report
- Albiglutide 50mg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI